Spero Therapeutics, Inc.

How big is Spero Therapeutics, Inc.?

As of Jun 18, Spero Therapeutics, Inc. has a market capitalization of 162.14 million and reported net sales of 28.31 million with a net profit of -69.77 million over the latest four quarters.

As of Jun 18, Spero Therapeutics, Inc. has a market capitalization of 162.14 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 28.31 million, while the sum of Net Profit for the same period is -69.77 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 46.12 million and Total Assets at 110.54 million.

What does Spero Therapeutics, Inc. do?

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections. As of March 2025, it reported net sales of $5 million and a net loss of $14 million, with a market cap of $162.14 million.

Overview: <BR>Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for multidrug-resistant (MDR) bacterial infections within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -14 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 162.14 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.39 <BR>Return on Equity: -203.20% <BR>Price to Book: 4.80 <BR><BR>Contact Details: <BR>Address: 675 Massachusetts Ave Ste 14, CAMBRIDGE MA: 02139-3309 <BR>Tel: ['1 857 2421600', '1 857 2421547'] <BR>Fax: 1 302 6555049 <BR>Website: https://sperotherapeutics.com/

Should I buy, sell or hold Spero Therapeutics, Inc.?

Who are in the management team of Spero Therapeutics, Inc.?

As of March 2022, the management team of Spero Therapeutics, Inc. includes Dr. Milind Deshpande (Independent Chairman), Dr. Ankit Mahadevia (President and CEO), and several Independent Directors: Dr. Jean-Francois Formela, Mr. Scott Jackson, Mr. John Pottage, Ms. Cynthia Smith, and Mr. Frank Thomas. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Spero Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Milind Deshpande, who serves as the Independent Chairman of the Board.<BR>- Dr. Ankit Mahadevia, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Jean-Francois Formela, who is an Independent Director.<BR>- Mr. Scott Jackson, who is also an Independent Director.<BR>- Mr. John Pottage, who serves as an Independent Director.<BR>- Ms. Cynthia Smith, who is an Independent Director.<BR>- Mr. Frank Thomas, who is an Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and governance.

Is Spero Therapeutics, Inc. overvalued or undervalued?

As of March 27, 2025, Spero Therapeutics, Inc. is considered overvalued with a risky valuation grade due to its high Price to Book Value of 4.13, negative EV to EBIT and EV to EBITDA ratios, and a low Return on Equity of -203.20%, despite a strong year-to-date stock return of 94.17%.

As of 27 March 2025, Spero Therapeutics, Inc. has moved from a fair to a risky valuation grade. The company is currently considered overvalued given its high Price to Book Value of 4.13 and negative EV to EBIT and EV to EBITDA ratios of -1.04, indicating significant financial challenges. Additionally, the company's Return on Equity (ROE) is alarmingly low at -203.20%, further underscoring its precarious financial position.<BR><BR>In comparison to peers, Spero Therapeutics has a worse EV to EBITDA ratio than Shattuck Labs, Inc. at -0.6631 and Enzo Biochem, Inc. at -0.1144, both of which also face risky valuations. Despite the company's strong year-to-date stock return of 94.17% compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a five-year return of -80.22% against the S&P 500's 96.61%.

Is Spero Therapeutics, Inc. technically bullish or bearish?

As of July 17, 2025, Spero Therapeutics, Inc. shows a mildly bullish trend with daily moving averages indicating positivity, despite mixed signals from weekly indicators and a bearish RSI, while outperforming the S&P 500 with a year-to-date return of 94.17%.

As of 17 July 2025, the technical trend for Spero Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend, while the weekly MACD and Bollinger Bands show a mildly bearish signal. The monthly MACD and Bollinger Bands are mildly bullish, suggesting some strength in the longer term. However, the RSI is bearish on a monthly basis, indicating potential weakness. <BR><BR>In terms of performance, Spero Therapeutics has outperformed the S&P 500 across multiple periods, with a year-to-date return of 94.17% compared to the S&P's 12.22%, and a one-year return of 49.25% versus 17.14% for the index.